IPOs and Secondaries
IPOs and Secondaries Articles
Blue Apron lowered its IPO price range, all the major U.S. financial companies put through stress tests by the Federal Reserve passed, and office supply company Staples has been sold.
Published:
Last Updated:
Blue Apron now expects to price 30 million shares in the range of $10 to $11 for an initial public offering valued up to almost $380 million.
Published:
Last Updated:
Bluebird Bio shares have made a steady gain over the course of the year and now the firm is looking to cash in on this growth.
Published:
Last Updated:
Blue Apron expects to price its 30 million shares in the range of $15 to $17 apiece, for an initial public offering valued up to more than $586 million.
Published:
Last Updated:
National yoga instruction company YogaWorks has registered with the SEC regarding its initial public offering.
Published:
Last Updated:
PetIQ, a maker of veterinarian-grade pet prescription medications, has filed with the SEC regarding its initial public offering.
Published:
Last Updated:
Metallurgical and steam coal provider Contura Energy has amended its filing with the SEC regarding its initial public offering.
Published:
Last Updated:
Altice USA entered the market with a bang in its initial public offering on Thursday, and shares were up further in Friday's premarket.
Published:
Last Updated:
Altice USA has entered the market in one of the largest initial public offerings (IPO) this year so far.
Published:
Last Updated:
Vencor Holding has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Clovis Oncology saw its shares make a handy gain in Wednesday’s session after the company priced its secondary offering.
Published:
Last Updated:
Investors who buy shares will be making the bet that the fourth largest U.S. cable operator will be able to leverage the money from this offering and grow in an environment with increasing...
Published:
Last Updated:
TPG RE Finance Trust has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Dova Pharmaceuticals intends to price its about 4 million shares in the range of $15 to $17 in an initial offering valued up to more than $79 million.
Published:
Last Updated:
Akcea Therapeutics expects to price more than 9 million shares in the range of $12 to $14 apiece in an initial public offering valued up to almost $155 million.
Published:
Last Updated: